NASDAQ:CEMIChembio Diagnostics Stock Price, Forecast & News

$8.94

-0.69 (-7.17 %)

(As of 06/1/2020 04:00 PM ET)

Add

Compare

Today's Range

$8.75

Now: $8.94▼

$9.60

50-Day Range

$8.08

MA: $11.77▼

$15.54

52-Week Range

$2.25

Now: $8.94▼

$15.89

Volume812,174 shs

Average Volume860,824 shs

Market Capitalization$156.89 million

P/E RatioN/A

Dividend YieldN/A

Beta2.31

Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases. The company offers tests for HIV and Syphilis, and Zika virus. It also develops tests for malaria, dengue virus, chikungunya virus, ebola, lassa, marburg, leptospirosis, Rickettsia typhi, Burkholderia pseudomallei, and Orientia tsutsugamushi. In addition, the company develops tests for a specific form of cancer, concussion, and bovine tuberculosis; and handheld optical analyzers for rapid diagnostic tests. It sells its products under the STAT-PAK, SURE CHECK, STAT VIEW, or DPP trademarks, as well as under the private labels of its marketing partners to medical laboratories and hospitals, governmental and public health entities, non-governmental organizations, medical professionals, and retail establishments in the United States and internationally. The company has collaboration agreements with Concussion Science Group Division of Perseus Science Group LLC to develop a POC diagnostic test for traumatic brain injury; Foundation for Innovative New Diagnostics to develop a POC fever panel assay for life-threatening acute febrile illnesses; AstraZeneca to develop a POC test for eosinophilic respiratory disease; and LumiraDx to develop POC diagnostic tests for infectious diseases. Chembio Diagnostics, Inc. was founded in 1985 and is headquartered in Medford, New York.

Beat the Market (BTM) Rank^™

3.4 Analyst's Opinion

Consensus Rating
Chembio Diagnostics has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $15.25, Chembio Diagnostics has a potential upside of 70.6% from its current price of $8.94.
Amount of Analyst Coverage
Chembio Diagnostics has only been the subject of 4 research reports in the past 90 days.

2.5 Community Rank

Outperform Votes
Chembio Diagnostics has received 264 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Chembio Diagnostics has received 256 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Chembio Diagnostics has received 50.77% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Chembio Diagnostics and other stocks. Vote “Outperform” if you believe CEMI will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CEMI will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Chembio Diagnostics does not currently pay a dividend.
Dividend Growth
Chembio Diagnostics does not have a long track record of dividend growth.

1.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Chembio Diagnostics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 4.90% of the stock of Chembio Diagnostics is held by insiders.
Percentage Held by Institutions
39.87% of the stock of Chembio Diagnostics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

3.1 Earnings and Valuation

Earnings Growth
Earnings for Chembio Diagnostics are expected to grow by 93.44% in the coming year, from $0.61 to $1.18 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Chembio Diagnostics is -9.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Chembio Diagnostics is -9.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Growth Ratio
Chembio Diagnostics has a PEG Ratio of 0.63. PEG Ratios below 1 indicate that a company could be undervalued.
Price to Book Value per Share Ratio
Chembio Diagnostics has a P/B Ratio of 6.53. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

2.00 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:CEMI

Previous Symbol

CUSIPN/A

CIK1092662

Webwww.chembio.com

Phone631-924-1135

Debt

Debt-to-Equity Ratio1.36

Current Ratio3.48

Quick Ratio2.11

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E Ratio14.66

P/E Growth0.63

Sales & Book Value

Annual Sales$34.46 million

Price / Sales4.55

Cash FlowN/A

Price / Cash FlowN/A

Book Value$1.37 per share

Price / Book6.53

Profitability

EPS (Most Recent Fiscal Year)($0.79)

Net Income$-13,680,000.00

Net Margins-48.02%

Return on Equity-63.13%

Return on Assets-29.41%

Miscellaneous

Employees295

Outstanding Shares17,549,000

Market Cap$156.89 million

Next Earnings Date8/4/2020 (Estimated)

OptionableNot Optionable

Receive CEMI News and Ratings via Email

Sign-up to receive the latest news and ratings for CEMI and its competitors with MarketBeat's FREE daily newsletter.

Chembio Diagnostics (NASDAQ:CEMI) Frequently Asked Questions

How has Chembio Diagnostics' stock been impacted by COVID-19 (Coronavirus)?

Chembio Diagnostics' stock was trading at $3.10 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CEMI stock has increased by 188.4% and is now trading at $8.94. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Chembio Diagnostics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chembio Diagnostics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Chembio Diagnostics.

When is Chembio Diagnostics' next earnings date?

Chembio Diagnostics is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Chembio Diagnostics.

How were Chembio Diagnostics' earnings last quarter?

Chembio Diagnostics Inc (NASDAQ:CEMI) announced its earnings results on Monday, May, 4th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.23) by $0.02. The business had revenue of $6.86 million for the quarter. Chembio Diagnostics had a negative return on equity of 63.13% and a negative net margin of 48.02%. View Chembio Diagnostics' earnings history.

What price target have analysts set for CEMI?

4 analysts have issued 1-year price targets for Chembio Diagnostics' shares. Their forecasts range from $7.00 to $21.00. On average, they expect Chembio Diagnostics' stock price to reach $15.25 in the next year. This suggests a possible upside of 70.6% from the stock's current price. View analysts' price targets for Chembio Diagnostics.

What are Wall Street analysts saying about Chembio Diagnostics stock?

Here are some recent quotes from research analysts about Chembio Diagnostics stock:

1. According to Zacks Investment Research, "CHEMBIO DIAGNOSTICS, INC. develops, manufactures, licenses and markets proprietary rapid diagnostic tests in the growing $5 billion point-of-care testing market. Chembio's two FDA PMA-approved, CLIA-waived, rapid HIV tests are marketed in the U.S. by a third party company. Chembio markets its HIV STAT-PAK line of rapid HIV tests internationally to government and donor-funded programs directly and through distributors. Chembio also has rapid tests for veterinary tuberculosis and chagas disease. In 2007 Chembio received a U.S. patent for its Dual Path Platform technology which has significant advantages over lateral-flow technologies. This technology is providing Chembio with a significant pipeline of business opportunities for the development and manufacture of new products based on DPP. Chembio is licensed by the U.S. Food and Drug Administration as well as the U. S. Department of Agriculture, and is certified for the global market under the International Standards Organization directive 13.485. " (4/24/2020)
2. Canaccord Genuity analysts commented, "We recently hosted Chembio CEO John Sperzel for two days of investor meetings. We believe Chembio possesses an underappreciated, compelling diagnostics platform that can be used for many new indications. For small cap mandates, we recommend investors get to know Chembio (at our conference on August 7th) as they target 25% top line revenue CAGR (through 2023) and materially improve GMs over the next 1-3 years. Trading at just 2.2x (vs. 4.6x peer average) our 2020 rev. estimate of $44M, we believe CEMI is an underappreciated small-cap growth stock, given its best-in-class test accuracy, unique ability to multiplex, and ability to provide quantitative results. We see upside from a number of global collaborations. We reiterate our BUY rating and $10 PT. HIV syphilis approval is a key 2H/19 catalyst." (7/22/2019)

Has Chembio Diagnostics been receiving favorable news coverage?

Media headlines about CEMI stock have been trending extremely positive recently, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Chembio Diagnostics earned a media sentiment score of 5.0 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news aboutChembio Diagnostics.

Are investors shorting Chembio Diagnostics?

Chembio Diagnostics saw a increase in short interest in May. As of May 15th, there was short interest totaling 813,900 shares, an increase of 18.7% from the April 30th total of 685,800 shares. Based on an average daily volume of 1,070,000 shares, the days-to-cover ratio is presently 0.8 days. Approximately 4.9% of the company's shares are short sold. View Chembio Diagnostics' Current Options Chain.

Who are some of Chembio Diagnostics' key competitors?

Some companies that are related to Chembio Diagnostics include Kala Pharmaceuticals (KALA), Ardelyx (ARDX), Provention Bio (PRVB), Homology Medicines (FIXX), G1 Therapeutics (GTHX), Vanda Pharmaceuticals (VNDA), Assembly Biosciences (ASMB), Morphic (MORF), ZIOPHARM Oncology (ZIOP), DiaMedica Therapeutics (DMCAF), Stemline Therapeutics (STML), Trillium Therapeutics (TRIL), Radius Health (RDUS), Syndax Pharmaceuticals (SNDX) and Passage Bio (IMRA). View all competitors.

What other stocks do shareholders of Chembio Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Chembio Diagnostics investors own include Prospect Capital (PSEC), Calumet Specialty Products Partners, L.P (CLMT), Two Harbors Investment (TWO), Blackrock Capital Investment (BKCC), Novocure (NVCR), Viper Energy Partners (VNOM), Summit Midstream Partners (SMLP), Washington Prime Group (WPG), Roper Technologies (ROP) and Rewalk Robotics (RWLK).

Who are Chembio Diagnostics' key executives?

Chembio Diagnostics' management team includes the following people:

Mr. John J. Sperzel III, Pres, CEO & Director (Age 55)
Mr. Neil A. Goldman, Exec. VP & CFO (Age 51)
Mr. Javan Esfandiari, Chief Science & Technology Officer and Exec. VP (Age 52)
Dr. Robert Passas Ph.D., Sr. VP & Chief Commercial Officer (Age 65)
Mr. David A. Gyorke, Sr. VP & COO (Age 59)

What is Chembio Diagnostics' stock symbol?

Chembio Diagnostics trades on the NASDAQ under the ticker symbol "CEMI."

Who are Chembio Diagnostics' major shareholders?

Chembio Diagnostics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Ingalls & Snyder LLC (1.50%), ARS Investment Partners LLC (1.31%), Penbrook Management LLC (1.11%), Millrace Asset Group Inc. (0.93%), Essex Investment Management Co. LLC (0.78%) and Conestoga Capital Advisors LLC (0.69%). Company insiders that own Chembio Diagnostics stock include Javan Esfandiari, John Gary Potthoff and Robert Passas. View institutional ownership trends for Chembio Diagnostics.

Which institutional investors are selling Chembio Diagnostics stock?

CEMI stock was sold by a variety of institutional investors in the last quarter, including ARS Investment Partners LLC, Wells Fargo & Company MN, Ingalls & Snyder LLC, UBS Group AG, and Essex Investment Management Co. LLC. View insider buying and selling activity for Chembio Diagnostics.

Which institutional investors are buying Chembio Diagnostics stock?

CEMI stock was acquired by a variety of institutional investors in the last quarter, including Millrace Asset Group Inc., EAM Investors LLC, Penbrook Management LLC, Jane Street Group LLC, Pinnacle Associates Ltd., White Pine Capital LLC, Fifth Third Bancorp, and Geode Capital Management LLC. Company insiders that have bought Chembio Diagnostics stock in the last two years include John Gary Potthoff, and Robert Passas. View insider buying and selling activity for Chembio Diagnostics.

How do I buy shares of Chembio Diagnostics?

Shares of CEMI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Chembio Diagnostics' stock price today?

One share of CEMI stock can currently be purchased for approximately $8.94.

How big of a company is Chembio Diagnostics?

Chembio Diagnostics has a market capitalization of $156.89 million and generates $34.46 million in revenue each year. The company earns $-13,680,000.00 in net income (profit) each year or ($0.79) on an earnings per share basis. Chembio Diagnostics employs 295 workers across the globe.

What is Chembio Diagnostics' official website?

The official website for Chembio Diagnostics is www.chembio.com.

How can I contact Chembio Diagnostics?

Chembio Diagnostics' mailing address is 555 WIRELESS BLVD., HAUPPAUGE NY, 11788. The company can be reached via phone at 631-924-1135 or via email at [email protected]

This page was last updated on 6/1/2020 by MarketBeat.com Staff